Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Drug development

Topic: Gut, metabolism and diet

Plain-language summary

Introduction Parkinsonism encompasses neurodegenerative disorders characterized by rigidity, tremor, and bradykinesia, with Parkinson’s disease (PD) accounting for most cases. Emerging evidence suggests that metabolic dysfunction, including insulin resistance and neuroinflammation, may contribute to PD pathogenesis. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for type 2 diabetes (T2D) and obesity, demonstrate neuroprotective effects in preclinical PD models. However, real-world evidence in individuals without T2D is limited. This study evaluated whether GLP-1RA use among adults with obesity or overweight is associated with the risk of PD and Parkinsonian disorders. Methods We conducted a retrospective cohort study using 2014-2024 electronic health record data from the OneFlorida+ Network. Adults with obesity (BMI ≥30 kg/m 2 ), overweight (BMI 25-29.9 kg/m 2 ) with a weight-related comorbidity, or an obesity diagnosis were eligible. Exclusions included age <50 years, <30 days of follow-up, baseline PD or Parkinsonism, anti-Parkinson medication use, or T2D. GLP-1RA users were matched 1:1 to non-users using time-conditional propensity scores. Outcomes were a composite of (1) PD/Parkinsonism and (2) any Parkinsonian-related disorder, including PD, Parkinsonism, Lewy body dementias, and multiple system atrophy. Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs). Results The matched cohort included 11,683 GLP-1RA users and 11,683 non-users with balanced characteristics and a median follow-up of 286 days. GLP-1RA use was not associated with reduced risk of PD or Parkinsonism (22 vs. 33 events; HR 0.70, 95% CI 0.41-1.22) or any Parkinsonian-related disorder (98 vs. 108 events; HR 0.96, 95% CI 0.73-1.27). Findings were consistent in subgroup and sensitivity analyses. Conclusion Among adults with obesity or overweight with a weight related condition, there was no difference in the risk of PD or Parkinsonian disorders between GLP-1 RA users and non-users. Longer follow-up and clinical trials are needed to clarify potential neuroprotective effects across populations.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Kotecha, P., Lee, Y. A., Presti, M. F., Guo, Y., Bian, J., & Guo, J. (2025). Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinsonian Disorders in Patients with Obesity. medRxiv. https://doi.org/10.64898/2025.11.24.25340763

Vancouver

Kotecha P, Lee YA, Presti MF, Guo Y, Bian J, Guo J. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinsonian Disorders in Patients with Obesity. medRxiv. 2025. doi:10.64898/2025.11.24.25340763.

BibTeX

@article{kotecha2025-0839901b,
  author  = {Kotecha, P. and Lee, Y. A. and Presti, M. F. and Guo, Y. and Bian, J. and Guo, J.},
  title   = {{Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinsonian Disorders in Patients with Obesity}},
  journal = {medRxiv},
  year    = {2025},
  doi     = {10.64898/2025.11.24.25340763},
  url     = {https://doi.org/10.64898/2025.11.24.25340763}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Study details

How this study scored 16/100
How this study's score is builtJournal tier 2 of 10; Journal's citation record 0 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 4 of 10; How recent 4 of 5; Sample size 4 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here left out, no data; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration left out, no data; Indexed in PubMed 1 of 2; Free to read 0 of 2. 31 of the 62 points it could be judged on, which is 50 of 100. Raw total 50 of 100, shown as 16 because this is not a peer-reviewed research article.raw total 50 of 100capped at 16 — hatched points do not count

Preprint — not yet peer-reviewed. It scored 50 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 31 of the 62 points we could judge it on, which is 50 out of 100.

ComponentPointsWhy
Journal tier 2 / 10 Tier 4 — not a peer-reviewed journal (medRxiv)
Journal's citation record 0 / 4 Not a journal article, so the journal's record does not count
Study design 7 / 12 A cohort study following people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 4 / 10 Preprint — not yet peer-reviewed. Hosted on a preprint server.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 4 / 4 11,683 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here — / 6 Not yet checked against this library's citation graph — left out of this score
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 0 / 2 Behind a paywall — scores zero
Points 31 / 62 Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 31 of the 62 points we could judge it on is 50 out of 100.
Total 50 / 100 Capped to 16 because this is not a peer-reviewed article.

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Drug development from nearby years

Also tagged “peptide-1”

285 studies in the library carry the topic tag “peptide-1”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 285 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Drug development

See all studies in Drug development →